Vision Retirement LLC Cuts Stock Holdings in Axon Enterprise, Inc $AXON

Vision Retirement LLC lowered its holdings in Axon Enterprise, Inc (NASDAQ:AXON) by 68.3% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 920 shares of the biotechnology company’s stock after selling 1,986 shares during the quarter. Vision Retirement LLC’s holdings in Axon Enterprise were worth $516,000 at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of the business. Guidance Capital Inc. purchased a new position in Axon Enterprise during the second quarter valued at approximately $537,000. Envestnet Portfolio Solutions Inc. lifted its holdings in Axon Enterprise by 239.1% during the second quarter. Envestnet Portfolio Solutions Inc. now owns 3,642 shares of the biotechnology company’s stock worth $2,042,000 after buying an additional 2,568 shares during the period. Physician Wealth Advisors Inc. lifted its holdings in Axon Enterprise by 1,922.2% during the second quarter. Physician Wealth Advisors Inc. now owns 364 shares of the biotechnology company’s stock worth $204,000 after buying an additional 346 shares during the period. Triumph Capital Management boosted its position in Axon Enterprise by 39.5% during the 2nd quarter. Triumph Capital Management now owns 339 shares of the biotechnology company’s stock valued at $190,000 after acquiring an additional 96 shares in the last quarter. Finally, IFP Advisors Inc boosted its position in Axon Enterprise by 11.3% during the 2nd quarter. IFP Advisors Inc now owns 1,632 shares of the biotechnology company’s stock valued at $915,000 after acquiring an additional 166 shares in the last quarter. Hedge funds and other institutional investors own 79.08% of the company’s stock.

More Axon Enterprise News

Here are the key news stories impacting Axon Enterprise this week:

• Positive Sentiment: Strong Q2 results and raised outlook: Axon exceeded expectations with adjusted earnings of $1.88 per share versus $1.84 expected and revenue of $904.4 million versus $876.4 million expected. Revenue grew 35.3% year over year, and management’s improved outlook supports the long-term growth story. Should You Buy, Hold or Sell AXON Stock Post Q2 Earnings Release?
• Positive Sentiment: Connected Devices momentum: TASER devices, body cameras and counter-drone products are driving strong hardware demand. Continued adoption of these products, combined with Axon’s cloud-based evidence and records software, reinforces the company’s integrated platform strategy. Will Strength in Connected Devices Unit Continue to Drive AXON’s Growth?
• Positive Sentiment: Bullish strategic commentary: Analysts highlighted Axon as a strong contender in law-enforcement technology, while coverage pointed to new artificial-intelligence capabilities as an additional growth catalyst for public-safety customers. Axon: A Strong Contender in Law Enforcement Tech
• Neutral Sentiment: Technical consolidation: AXON remains in a strong broader uptrend but has recently consolidated, leaving investors watching whether momentum resumes or the rally pauses. Stock of the Day: Is the Axon Rally Over?
• Negative Sentiment: Valuation and profitability risks: Despite strong revenue growth, analysts cautioned that Axon’s high earnings multiple, elevated costs, debt and relatively modest margins reduce its near-term appeal. Memory costs and counter-drone investments could also pressure profitability if spending rises faster than sales.
• Negative Sentiment: CEO share sale: CEO Patrick Smith sold 9,930 shares worth approximately $5.45 million. The transaction occurred under a pre-arranged Rule 10b5-1 plan and represented only 0.33% of his holdings, making it a limited signal but a potential source of investor caution.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on AXON shares. JPMorgan Chase & Co. boosted their price target on Axon Enterprise from $750.00 to $755.00 and gave the stock an “overweight” rating in a research report on Thursday, May 7th. Barclays raised their price objective on Axon Enterprise from $523.00 to $688.00 and gave the company an “overweight” rating in a research report on Thursday, August 6th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Axon Enterprise in a research note on Wednesday, August 5th. The Goldman Sachs Group reiterated a “buy” rating and issued a $715.00 target price on shares of Axon Enterprise in a report on Thursday, August 6th. Finally, Zacks Research lowered shares of Axon Enterprise from a “strong-buy” rating to a “hold” rating in a research report on Friday, July 10th. Thirteen analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $730.92.

Axon Enterprise Price Performance

NASDAQ AXON opened at $615.59 on Friday. The firm’s fifty day simple moving average is $523.52 and its two-hundred day simple moving average is $473.43. The company has a current ratio of 2.15, a quick ratio of 1.80 and a debt-to-equity ratio of 0.47. Axon Enterprise, Inc has a 12-month low of $339.01 and a 12-month high of $794.29. The firm has a market capitalization of $50.01 billion, a P/E ratio of 255.43, a P/E/G ratio of 12.24 and a beta of 1.39.

Axon Enterprise (NASDAQ:AXON) last issued its quarterly earnings data on Tuesday, August 4th. The biotechnology company reported $1.88 EPS for the quarter, beating the consensus estimate of $1.84 by $0.04. Axon Enterprise had a return on equity of 2.84% and a net margin of 6.19%.The firm had revenue of $904.39 million during the quarter, compared to analyst estimates of $876.42 million. During the same quarter in the prior year, the business posted $2.12 EPS. The business’s revenue for the quarter was up 35.3% compared to the same quarter last year. Analysts forecast that Axon Enterprise, Inc will post 1.63 EPS for the current fiscal year.

Insider Activity

In related news, insider Elizabeth Reid Coughlin sold 1,554 shares of the company’s stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $485.00, for a total transaction of $753,690.00. Following the transaction, the insider directly owned 34,024 shares of the company’s stock, valued at $16,501,640. This represents a 4.37% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CRO Cameron Brooks sold 1,242 shares of the stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $500.00, for a total value of $621,000.00. Following the completion of the sale, the executive owned 49,710 shares of the company’s stock, valued at approximately $24,855,000. This trade represents a 2.44% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 68,989 shares of company stock worth $36,016,932 over the last quarter. Company insiders own 4.20% of the company’s stock.

About Axon Enterprise

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.